UNSPSC 51273830: Antipyrine and benzocaine solution

This classification denotes a combination drug. The arug consists of two components. The first is PHENAZONE or PHENAZON or ANTIPYRINE or ANALGESINE, a nonsteroidal antiinflammatory drug with the molecular formula C11H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3CHA1B51H, chemically known as 2,3-dimethyl-1-phenylpyrazol-5-one but generally known as antipyrine, which bears US NIH Compound Identifier 2206. Antipyrine most often comes in base, iodide, and salicylate forms.

UNSPSC 51273830 Antipyrine and benzocaine solution is a Commodity code that captures pharmaceutical products, though recent state and local solicitations tagged under it reflect a broader pharmaceuticals and therapeutic supply procurement landscape rather than this specific otic/topical anesthetic formulation alone. State and local buyers soliciting under or near this code are acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements, and establishing direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of multiple state and local participating members across Minnesota and Oregon). The work spans procurement of finished pharmaceutical products for community health and emergency response initiatives, inventory supply through authorized wholesaler networks, and exploratory vendor engagement for alternative pharmacy benefit program structures.

Recent activity is concentrated in Florida, Texas, and the Upper Midwest. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no formal award timeline specified in this preliminary information-gathering phase. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Vendors pursuing this code should expect requirements for cGMP and DSCSA compliance, E-Verify verification, comprehensive insurance coverage, and participation in authorized wholesaler networks where applicable.